News | Cardiovascular Business | February 25, 2019| Jeff Zagoudis, Associate Editor

GE to Postpone Healthcare IPO Following Biopharmaceutical Business Sale

CEO Larry Culp Jr. says 2019 spinoff of healthcare division “unlikely” as company focuses on finishing $21.4 billion biopharma sale to Danaher by end of the year

GE to Postpone Healthcare IPO Following Biopharmaceutical Business Sale

February 25, 2019 — GE Healthcare announced Feb. 25 the sale of its biopharmaceutical business to Danaher, and GE Chairman and CEO Larry Culp Jr. said the deal signified that a planned 2019 initial public offering (IPO) for GE Healthcare is now unlikely. GE is reportedly weighing its options following the deal, which casts off the biopharmaceutical business for $21.4 billion.

“We are focused on completing the carve out [of the biopharma business] — which is 15 percent of the $20 billion healthcare segment — and focused on managing the remaining core business,” Culp told CNBC. Culp previously served as CEO at Danaher — a global science and technology company in the fields of environmental and applied solutions, life sciences, diagnostics and dental — from 2001 to 2014. He was named to the top position at GE in October 2018 to replace previous CEO John Flannery, who was removed after just 14 months on the job.

The biopharmaceutical business is part of GE Life Sciences and generated approximately $3 billion in revenue for the parent company in 2018. This branch manufactures instruments, consumables and software to support the research, discovery, process development and manufacturing workflows of biopharmaceutical drugs. The company said its pharmaceutical diagnostics business, which supplies contrast media and molecular imaging consumables for radiology customers, will remain within the GE Healthcare portfolio.

GE first announced plans to spin off its healthcare division into a standalone company in June 2018. The move is part of attempts by the multinational conglomerate to streamline its operations and refocus on its core industrial and energy businesses in the face of financial difficulties in recent years. Healthcare has been one of GE’s most profitable businesses recently, generating approximately $19 billion in revenue and $3.4 billion in profit in 2018. In 2017, the division was responsible for nearly 16 percent of the parent company’s total sales and more than 43 percent of its operating profit, according to CNBC.

Wall Street reported that news of the biopharmaceutical sale caused GE’s stock to jump as much as 16 percent on Monday, reaching levels not seen since last October. Overall, analysts say the parent company’s shares have advanced 34 percent in 2019 as of Feb. 22.

GE Healthcare President and CEO Kieran Murphy said in a statement, “The biopharma business has been a strong contributor to our success, and I am confident this agreement represents a great opportunity for our valued colleagues to flourish under the ownership of Danaher. GE Healthcare has unsurpassed scale and scope and we will continue to focus on our investments so that we deliver better outcomes and more capacity to a world striving for precision health.”

GE expects to complete the sale to Danaher by the end of 2019.

For more information: www.gehealthcare.com

Related Content

ACC Combines NCDR, Accreditation Into New Quality Summit
News | Cardiovascular Business | March 15, 2019
The American College of Cardiology’s first annual ACC Quality Summit, held March 13-15 in New Orleans, merges the NCDR...
Diagnostic and Interventional Cardiology Named 2019 Azbee Awards Finalist for Social Media
News | Cardiovascular Business | March 08, 2019 | Jeff Zagoudis, Associate Editor
Diagnostic and Interventional Cardiology (DAIC) was named a finalist in the Social Media Presence category for the 2019...
 FDA Commissioner Scott Gottlieb Announces Resignation
News | Cardiovascular Business | March 05, 2019 | Jeff Zagoudis, Associate Editor
U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, M.D., resigned from his position March 5 after two...
Diagnostic and Interventional Cardiology Honored as Jesse H. Neal Awards Finalist

An example of the new transesophageal echo (TEE) visualization technology called TrueVue was shown at TCT 2018 for the first time. Philips’ new photo-realistic rendering is designed to offer a surgical view of cardiac structures to aid transcatheter procedural navigation.

News | Cardiovascular Business | February 25, 2019
Diagnostic and Interventional Cardiology has been recognized as a finalist in the Jesse H. Neal Awards for the third...
Medical Bills Financially Burden Almost Half of Cardiovascular Disease Patients
News | Cardiovascular Business | February 11, 2019
Over 45 percent of adult atherosclerotic cardiovascular disease (ASCVD) patients suffer financial hardship related to...
Researchers raised the question whether an economic benefit should be assessed in FDA reviews. A large amount of the bill for atrial fibrillation catheter ablation procedures is the cost of the mapping and ablation catheters.

A large amount of the bill for atrial fibrillation catheter ablation procedures is the cost of the mapping and ablation catheters. Researchers raised the question whether an economic benefit should be assessed in FDA reviews. 

Feature | Cardiovascular Business | January 14, 2019 | Philip Jacobs, DPhil, Ilke Akpinar, M.D., Thanh Nguyen, M.D., Ph.D., Rupinder Sandhu, M.D., and Lars Thording Ph.D.
In an age when everything in medicine is now looked at though a cost vs. benefit analysis and U.S.
GE Submits Initial Public Offering Paperwork for Healthcare Division
News | Cardiovascular Business | December 19, 2018
As part of its plans to spin off its healthcare division into a separate company, GE reportedly submitted the paperwork...
Affordable Care Act Ruled Unconstitutional in Texas Federal Court
News | Cardiovascular Business | December 17, 2018
A judge of the Federal District Court for the Northern District of Texas ruled the Affordable Care Act (ACA)...
Average Age of U.S. Cardiologists Up While Income is Down
News | Cardiovascular Business | October 25, 2018
Overall cardiology compensation has dropped for the first time since 2014, according to the sixth annual Cardiovascular...
Overlay Init